Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Text Size

Tipranavir/Ritonavir vs. Genotypically Defined Protease Inhibitor/Ritonavir in HIV Patients (RESIST-2)

This study has been completed.
Sponsor:
Information provided by:
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT00144170
First received: September 2, 2005
Last updated: June 23, 2014
Last verified: April 2014
History of Changes
Results First Received: September 11, 2009  
Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment
Condition: HIV Infections
Interventions: Drug: Tipranavir (with low dose ritonavir)
Drug: Comparator protease inhibitor(CPI)/low dose ritonavir(r)

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
The discrepancy with enrollment number in the protocol section is due to 16 patients not treated. (7 from TPV/r and 9 from CPI/r). These patients were not included in any analyses or results.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Tipranavir(TPV)/Low Dose Ritonavir(r) No text entered.
Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r) No text entered.

Participant Flow:   Overall Study
    Tipranavir(TPV)/Low Dose Ritonavir(r)     Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)  
STARTED     438     428  
COMPLETED     86     32  
NOT COMPLETED     352     396  
Adverse Event                 84                 41  
Protocol Violation                 23                 16  
Lost to Follow-up                 5                 10  
Withdrawal by Subject                 29                 13  
Other reason not defined above                 211                 316  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Tipranavir(TPV)/Low Dose Ritonavir(r) No text entered.
Comparitor Protease Inhibitor(CPI)/Low Dose Ritonavir(r) No text entered.
Total Total of all reporting groups

Baseline Measures
    Tipranavir(TPV)/Low Dose Ritonavir(r)     Comparitor Protease Inhibitor(CPI)/Low Dose Ritonavir(r)     Total  
Number of Participants  
[units: participants]
 		  435     428     863  
Age [1]
[units: years]
Mean (Standard Deviation) 		  42.5  (8.4)     42.9  (8)     42.7  (8.2)  
Gender [1]
[units: participants]
 		     
Female     84     64     148  
Male     351     364     715  
[1] 3 patients were not randomized but treated with TPV/r. They are included in the participant flow and adverse events but not in the efficacy analysis.



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Treatment Response at Week 48   [ Time Frame: after 48 weeks of treatment ]
  Show Outcome Measure 1

2.  Primary:   Time to Treatment Failure Through 48 Weeks of Treatment   [ Time Frame: after 48 weeks of treatment ]
  Show Outcome Measure 2

3.  Secondary:   Treatment Response at Week 2   [ Time Frame: week 2 ]
  Show Outcome Measure 3

4.  Secondary:   Treatment Response at Week 4   [ Time Frame: week 4 ]
  Show Outcome Measure 4

5.  Secondary:   Treatment Response at Week 8   [ Time Frame: week 8 ]
  Show Outcome Measure 5

6.  Secondary:   Treatment Response at Week 16   [ Time Frame: week 16 ]
  Show Outcome Measure 6

7.  Secondary:   Treatment Response at Week 24   [ Time Frame: Week 24 ]
  Show Outcome Measure 7

8.  Secondary:   Treatment Response at Week 32   [ Time Frame: week 32 ]
  Show Outcome Measure 8

9.  Secondary:   Treatment Response at Week 40   [ Time Frame: week 40 ]
  Show Outcome Measure 9

10.  Secondary:   Treatment Response at Week 56   [ Time Frame: week 56 ]
  Show Outcome Measure 10

11.  Secondary:   Treatment Response at Week 64   [ Time Frame: week 64 ]
  Show Outcome Measure 11

12.  Secondary:   Treatment Response at Week 72   [ Time Frame: week 72 ]
  Show Outcome Measure 12

13.  Secondary:   Treatment Response at Week 80   [ Time Frame: week 80 ]
  Show Outcome Measure 13

14.  Secondary:   Treatment Response at Week 88   [ Time Frame: week 88 ]
  Show Outcome Measure 14

15.  Secondary:   Treatment Response at Week 96   [ Time Frame: after 96 weeks of treatment ]
  Show Outcome Measure 15

16.  Secondary:   Time to Treatment Failure Through 96 Weeks of Treatment   [ Time Frame: after 96 weeks of treatment ]
  Show Outcome Measure 16

17.  Secondary:   Time to Confirmed Virologic Failure Through 48 Weeks of Treatment   [ Time Frame: after 48 weeks of treatment ]
  Show Outcome Measure 17

18.  Secondary:   Time to Confirmed Virologic Failure Through 96 Weeks of Treatment   [ Time Frame: after 96 weeks of treatment ]
  Show Outcome Measure 18

19.  Secondary:   Virologic Response   [ Time Frame: Week 2 through Week 96 (at any point during trial) ]
  Show Outcome Measure 19

20.  Secondary:   Virologic Response at Week 2   [ Time Frame: Week 2 ]
  Show Outcome Measure 20

21.  Secondary:   Virologic Response at Week 4   [ Time Frame: week 4 ]
  Show Outcome Measure 21

22.  Secondary:   Virologic Response at Week 8   [ Time Frame: week 8 ]
  Show Outcome Measure 22

23.  Secondary:   Virologic Response at Week 16   [ Time Frame: week 16 ]
  Show Outcome Measure 23

24.  Secondary:   Virologic Response at Week 24   [ Time Frame: week 24 ]
  Show Outcome Measure 24

25.  Secondary:   Virologic Response at Week 32   [ Time Frame: week 32 ]
  Show Outcome Measure 25

26.  Secondary:   Virologic Response at Week 40   [ Time Frame: week 40 ]
  Show Outcome Measure 26

27.  Secondary:   Virologic Response at Week 48   [ Time Frame: week 48 ]
  Show Outcome Measure 27

28.  Secondary:   Virologic Response at Week 56   [ Time Frame: week 56 ]
  Show Outcome Measure 28

29.  Secondary:   Virologic Response at Week 64   [ Time Frame: week 64 ]
  Show Outcome Measure 29

30.  Secondary:   Virologic Response at Week 72   [ Time Frame: Week 72 ]
  Show Outcome Measure 30

31.  Secondary:   Virologic Response at Week 80   [ Time Frame: Week 80 ]
  Show Outcome Measure 31

32.  Secondary:   Virologic Response at Week 88   [ Time Frame: Week 88 ]
  Show Outcome Measure 32

33.  Secondary:   Virologic Response at Week 96   [ Time Frame: Week 96 ]
  Show Outcome Measure 33

34.  Secondary:   Median Change From Baseline in Viral Load (Week 2)   [ Time Frame: Baseline to Week 2 ]
  Show Outcome Measure 34

35.  Secondary:   Median Change From Baseline in Viral Load (Week 4)   [ Time Frame: Baseline to Week 4 ]
  Show Outcome Measure 35

36.  Secondary:   Median Change From Baseline in Viral Load (Week 8)   [ Time Frame: Baseline to Week 8 ]
  Show Outcome Measure 36

37.  Secondary:   Median Change From Baseline in Viral Load (Week 16)   [ Time Frame: Baseline to Week 16 ]
  Show Outcome Measure 37

38.  Secondary:   Median Change From Baseline in Viral Load (Week 24)   [ Time Frame: Baseline to Week 24 ]
  Show Outcome Measure 38

39.  Secondary:   Median Change From Baseline in Viral Load (Week 32)   [ Time Frame: Baseline to Week 32 ]
  Show Outcome Measure 39

40.  Secondary:   Median Change From Baseline in Viral Load (Week 40)   [ Time Frame: Baseline to Week 40 ]
  Show Outcome Measure 40

41.  Secondary:   Median Change From Baseline in Viral Load (Week 48)   [ Time Frame: Baseline to Week 48 ]
  Show Outcome Measure 41

42.  Secondary:   Median Change From Baseline in Viral Load (Week 56)   [ Time Frame: Baseline to Week 56 ]
  Show Outcome Measure 42

43.  Secondary:   Median Change From Baseline in Viral Load (Week 64)   [ Time Frame: Baseline to Week 64 ]
  Show Outcome Measure 43

44.  Secondary:   Median Change From Baseline in Viral Load (Week 72)   [ Time Frame: Baseline to Week 72 ]
  Show Outcome Measure 44

45.  Secondary:   Median Change From Baseline in Viral Load (Week 80)   [ Time Frame: Baseline to Week 80 ]
  Show Outcome Measure 45

46.  Secondary:   Median Change From Baseline in Viral Load (Week 88)   [ Time Frame: Baseline to Week 88 ]
  Show Outcome Measure 46

47.  Secondary:   Median Change From Baseline in Viral Load (Week 96)   [ Time Frame: Baseline to Week 96 ]
  Show Outcome Measure 47

48.  Secondary:   Virologic Response at Week 40   [ Time Frame: Week 40 ]
  Show Outcome Measure 48

49.  Secondary:   Virologic Response at Viral Load Nadir During Study Treatment Through 96 Weeks   [ Time Frame: Week 2 through Week 96 (at any point during trial) ]
  Show Outcome Measure 49

50.  Secondary:   Virologic Response at Week 2   [ Time Frame: Week 2 ]
  Show Outcome Measure 50

51.  Secondary:   Virologic Response at Week 4   [ Time Frame: Week 4 ]
  Show Outcome Measure 51

52.  Secondary:   Virologic Response at Week 8   [ Time Frame: Week 8 ]
  Show Outcome Measure 52

53.  Secondary:   Virologic Response at Week 16   [ Time Frame: Week 16 ]
  Show Outcome Measure 53

54.  Secondary:   Virologic Response at Week 24   [ Time Frame: Week 24 ]
  Show Outcome Measure 54

55.  Secondary:   Virologic Response at Week 32   [ Time Frame: Week 32 ]
  Show Outcome Measure 55

56.  Secondary:   Virologic Response at Week 48   [ Time Frame: Week 48 ]
  Show Outcome Measure 56

57.  Secondary:   Virologic Response at Week 56   [ Time Frame: Week 56 ]
  Show Outcome Measure 57

58.  Secondary:   Virologic Response at Week 64   [ Time Frame: Week 64 ]
  Show Outcome Measure 58

59.  Secondary:   Virologic Response at Week 72   [ Time Frame: Week 72 ]
  Show Outcome Measure 59

60.  Secondary:   Virologic Response at Week 80   [ Time Frame: Week 80 ]
  Show Outcome Measure 60

61.  Secondary:   Virologic Response at Week 88   [ Time Frame: week 88 ]
  Show Outcome Measure 61

62.  Secondary:   Virologic Response at Week 96   [ Time Frame: week 96 ]
  Show Outcome Measure 62

63.  Secondary:   Virologic Response   [ Time Frame: Week 2 through Week 96 (at any point during trial) ]
  Show Outcome Measure 63

64.  Secondary:   Virologic Response at Week 2   [ Time Frame: Week 2 ]
  Show Outcome Measure 64

65.  Secondary:   Virologic Response at Week 4   [ Time Frame: Week 4 ]
  Show Outcome Measure 65

66.  Secondary:   Virologic Response at Week 8   [ Time Frame: Week 8 ]
  Show Outcome Measure 66

67.  Secondary:   Virologic Response at Week 16   [ Time Frame: Week 16 ]
  Show Outcome Measure 67

68.  Secondary:   Virologic Response at Week 24   [ Time Frame: Week 24 ]
  Show Outcome Measure 68

69.  Secondary:   Virologic Response at Week 32   [ Time Frame: Week 32 ]
  Show Outcome Measure 69

70.  Secondary:   Virologic Response at Week 40   [ Time Frame: Week 40 ]
  Show Outcome Measure 70

71.  Secondary:   Virologic Response at Week 48   [ Time Frame: Week 48 ]
  Show Outcome Measure 71

72.  Secondary:   Virologic Response at Week 56   [ Time Frame: Week 56 ]
  Show Outcome Measure 72

73.  Secondary:   Virologic Response at Week 64   [ Time Frame: Week 64 ]
  Show Outcome Measure 73

74.  Secondary:   Virologic Response at Week 72   [ Time Frame: Week 72 ]
  Show Outcome Measure 74

75.  Secondary:   Virologic Response at Week 80   [ Time Frame: Week 80 ]
  Show Outcome Measure 75

76.  Secondary:   Virologic Response at Week 88   [ Time Frame: Week 88 ]
  Show Outcome Measure 76

77.  Secondary:   Virologic Response at Week 96   [ Time Frame: Week 96 ]
  Show Outcome Measure 77

78.  Secondary:   Mean Change From Baseline in CD4+ Cell Count (Week 2)   [ Time Frame: Baseline to Week 2 ]
  Show Outcome Measure 78

79.  Secondary:   Mean Change From Baseline in CD4+ Cell Count (Week 4)   [ Time Frame: Baseline to Week 4 ]
  Show Outcome Measure 79

80.  Secondary:   Mean Change From Baseline in CD4+ Cell Count (Week 8)   [ Time Frame: Baseline to Week 8 ]
  Show Outcome Measure 80

81.  Secondary:   Mean Change From Baseline in CD4+ Cell Count (Week 16)   [ Time Frame: Baseline to Week 16 ]
  Show Outcome Measure 81

82.  Secondary:   Mean Change From Baseline in CD4+ Cell Count (Week 24)   [ Time Frame: Baseline to Week 24 ]
  Show Outcome Measure 82

83.  Secondary:   Mean Change From Baseline in CD4+ Cell Count (Week 32)   [ Time Frame: Baseline to Week 32 ]
  Show Outcome Measure 83

84.  Secondary:   Mean Change From Baseline in CD4+ Cell Count (Week 40)   [ Time Frame: Baseline to Week 40 ]
  Show Outcome Measure 84

85.  Secondary:   Mean Change From Baseline in CD4+ Cell Count (Week 48)   [ Time Frame: Baseline to Week 48 ]
  Show Outcome Measure 85

86.  Secondary:   Mean Change From Baseline in CD4+ Cell Count (Week 56)   [ Time Frame: Baseline to Week 56 ]
  Show Outcome Measure 86

87.  Secondary:   Mean Change From Baseline in CD4+ Cell Count (Week 64)   [ Time Frame: Baseline to Week 64 ]
  Show Outcome Measure 87

88.  Secondary:   Mean Change From Baseline in CD4+ Cell Count (Week 72)   [ Time Frame: Baseline to Week 72 ]
  Show Outcome Measure 88

89.  Secondary:   Mean Change From Baseline in CD4+ Cell Count (Week 80)   [ Time Frame: Baseline to Week 80 ]
  Show Outcome Measure 89

90.  Secondary:   Mean Change From Baseline in CD4+ Cell Count (Week 88)   [ Time Frame: Baseline to Week 88 ]
  Show Outcome Measure 90

91.  Secondary:   Mean Change From Baseline in CD4+ Cell Count (Week 96)   [ Time Frame: Baseline to Week 96 ]
  Show Outcome Measure 91

92.  Secondary:   Time to New Centers for Disease Control (CDC) Class C Progression Event or Death.   [ Time Frame: up to 75 weeks of treatment ]
  Show Outcome Measure 92


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Boehringer Ingelheim Call Center
Organization: Boehringer Ingelheim Pharmaceuticals
phone: 1-800-243-0127
e-mail: clintriage.rdg@boehringer-ingelheim.com


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):


Responsible Party: Boehringer Ingelheim, Study Chair, Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT00144170     History of Changes
Other Study ID Numbers: 1182.48
RESIST 2
Study First Received: September 2, 2005
Results First Received: September 11, 2009
Last Updated: June 23, 2014
Health Authority: Argentina: Admin Nacional de Medicamentos, Alimentos Tecnologia Medica
Austria: Bundesministerium fuer soziale Sicherheit und Generationen
Belgium: Federal Agency for Medicines and Health Products, FAMHP
Brazil: Ministry of Health
Denmark: Danish Medicines Agency
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Germany: BfArM-Bundesinstitut fuer Arzneimittel und Medizinprodukte (Federal Authoriteis for Drugs and Medica
Greece: National Organization of Medicines
Ireland: Irish Medicines Board
Italy: Comitato Etico della Fondazione Centro San Raffaele del Monte Tabor - Milano
Mexico: Federal Commission for Protection Against Health Risks
Netherlands: Central Committee Research Involving Human Subjects
Portugal: INFARMED I.P. Parque da Saúde de Lisboa Av. do Brasil, nº 53 1749-004 Lisboa
Spain: Spanish Agency of Medicines
Sweden: Medical Products Agency
Switzerland: Swissmedic
United Kingdom: Medicines and Healthcare Products Regulatory Agency
United States: Food and Drug Administration